2100 EAST 54TH STREET NORTH, SIOUX FALLS, SD
Master Manufacturing Services Agreement with Emergent BioSolutions
Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026
Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
Reg. FD, Other Events
Investor Presentation
Strengthens Board of Directors with Appointment of New Chair and New Director
Other Events
News
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Correspondence
Submission Upload